证券代码：603970 证券简称：中农立华 公告编号：2025-021 中农立华生物科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 5 月 16 日 (二) 股东大会召开的地点：北京市西城区宣武门外大街甲 1 号环球财讯 中心会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情 况： | 1、出席会议的股东和代理人人数 | 116 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 168,344,112 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 62.6279 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情 况等。 本次会议由公司董事会召集，董事长苏毅先生主持。会议表决为现场表决和 网络表决相结合的方式，符合《公司法》和《公司章程 ...

关于 中农立华生物科技股份有限公司 2024 年年度股东大会见证之 法律意见书 北京市东城区金宝街 89 号金宝大厦 11 层邮编：100005 11F，JinbaoTower，89JinbaoStreet，DongchengDistrict，Beijing100005，P.R.C. 电话（Tel）：（86-10）66523388 传真（Fax）：（86-10）66523399 网址（Website）：www.junzejun.com 电子信箱（E-mail）：jzj@junzejun.com 法律意见书 北京市君泽君律师事务所 关于 中农立华生物科技股份有限公司 2024 年年度股东大会见证之 法律意见书 致：中农立华生物科技股份有限公司 北京市君泽君律师事务所（以下简称"本所"）受中农立华生物科技股份有限 公司（以下简称"公司"）委托，指派本所律师出席公司 2024 年年度股东大会（以 下简称"本次股东大会"），就本次公司股东大会召集、召开程序、出席本次股东 大会人员的资格以及本次股东大会的表决程序、表决结果进行见证，并出具本法 律意见书。 为出具本法律意见书，本所律师特作出如下声明： 1、本所及本所律师 ...

Core Points - The company is preparing for the 2024 Annual General Meeting (AGM) to discuss various proposals including financial reports, profit distribution, and governance changes [2][3][4] Proposal Summaries - Proposal 1: The company will present the 2024 Board of Directors' Work Report for shareholder approval [3] - Proposal 2: The company will present the 2024 Supervisory Board's Work Report for shareholder approval [3] - Proposal 3: The company will present the 2024 Annual Report and its summary for shareholder approval [3] - Proposal 4: The company will present the 2024 Financial Settlement Report for shareholder approval [3] - Proposal 5: The company proposes a profit distribution plan, distributing cash dividends of RMB 4.50 per 10 shares, totaling RMB 120 million, which is 59.48% of the net profit [3] - Proposal 6: The company will confirm the salaries and allowances for non-independent directors and senior management for 2024, with the chairman receiving RMB 145.41 million [3] - Proposal 7: The company will confirm the salaries and allowances for independent directors for 2024, with the highest being RMB 6.72 million [3] - Proposal 8: The company proposes to reappoint Tianzhi International Accounting Firm for the 2025 financial report and internal control audit, with fees totaling RMB 1 million [4] - Proposal 9: The company plans to use idle funds for cash management to enhance investment returns [4] - Proposal 10: The company will review the execution of daily related transactions for 2024 and the expected amount for 2025 [5] - Proposal 11: The company plans to conduct foreign exchange hedging with a total amount not exceeding RMB 2 billion [6] - Proposal 12: The company plans to provide guarantees for its subsidiary, with amounts not exceeding RMB 2 billion for one subsidiary and RMB 3 billion for another [7] - Proposal 13: The company will sign a financial service agreement with Supply and Marketing Group Financial Co., Ltd. to improve liquidity [8] - Proposal 14: The company plans to change its business scope and amend its articles of association [9] - Proposal 15: The company will revise the rules of procedure for board meetings and shareholder meetings [10] - Proposal 16: The company will revise the independent director working rules and other governance systems [12] - Proposal 17: The company proposes to abolish the supervisory board and its rules [13] Financial Performance - The company reported a revenue of RMB 1,059,581.84 million for the year, an increase of 1.30% compared to the previous year [14] - The raw material prices in the agricultural chemical industry have decreased, with the raw material price index dropping by 9.07% year-on-year [14]

二〇二四年年度股东大会 会议议案 议案一：关于公司《2024 年度董事会工作报告》的议案 中农立华生物科技股份有限公司 二〇二四年年度股东大会 会议材料 2025.5 北京 | | | | 附件二：2024 年度独立董事述职报告（潘爱香） 26 | | --- | | 附件三：2024 年度独立董事述职报告（吴学民） 32 | | 附件四：2024 年度独立董事述职报告（刘玉玖） 38 | | 附件五：2024 年度独立董事述职报告（胡燕） 45 | | 附件六：2024 年度监事会工作报告 51 | | 附件七：2024 年度财务决算报告 56 | | 附件八：关于天职国际会计师事务所（特殊普通合伙）的情况说明 64 | | 附件九：关于使用闲置自有资金进行现金管理的报告 67 | | 附件十：日常关联交易 年度执行情况及 2024 2025 年度预计额度的报告..70 | | 附件十一：控股股东及其他关联方资金占用情况的专项说明 74 | | 年度涉 及 财 务 公 司 关 联 交 易 的 存 款 、 贷 款 等 金 融 附件十二：2024 | | 业 务 的 专 项 说 明 78 | | 附件十三：关于 ...

中农立华生物科技股份有限公司 投资者关系活动记录表 编号：2025-02 | | ☑特定对象调研 | 分析师会议 | | --- | --- | --- | | 投资者关系活 | 媒体采访 | ☑业绩说明会 | | 动类别 | 新闻发布会 | ☑路演活动 | | | ☑现场参观 | ☑网络会议 | | | ☑一对一沟通 | 其他 | | | 中信证券股份有限公司 | 孙臣兴、田显城 | | | 招商信诺资产管理有限公司 | 钱旖昕 | | | 中泰证券股份有限公司 | 王鹏 | | | 民生证券股份有限公司 | 李家豪 | | | 国泰海通证券股份有限公司 | 钱伟伦 | | | 中国国际金融股份有限公司 | 吴頔 | | | 东北证券股份有限公司 | 孙鹏程 | | 参与单位名称 | 华创证券有限责任公司 | 吴宇、陈鹏 | | 及人员姓名 | 国金证券股份有限公司 | 王明辉 | | | 开源证券股份有限公司 | 徐正凤 | | | 国海证券股份有限公司 | 曾子华 | | | 国海证券股份有限公司 | 王毅 | | | 华福证券有限责任公司 | 魏征宇 | | | 中泰证券股份有限公司 | 潘云 ...

Core Viewpoint - The company, Zhongnong Lihua, emphasizes the accuracy and completeness of its quarterly report, ensuring no false records or misleading statements exist [2][3]. Financial Data - The quarterly financial statements for the first quarter of 2025 are unaudited, with no significant changes in major accounting data and financial indicators reported [3][4]. - The company reported a net profit of 0.00 yuan for the merged entity in the current and previous periods [5]. Shareholder Information - There are no changes reported in the top ten shareholders or any significant movements in share lending activities [4][5]. Other Important Information - The company has not identified any additional important information regarding its operational performance during the reporting period [5][6].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 2,532,148,049.31, representing a year-on-year increase of 5.62% compared to CNY 2,397,490,584.10 in the same period last year[3] - The net profit attributable to shareholders of the listed company decreased by 5.10% to CNY 53,936,654.66 from CNY 56,835,448.06 in the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 50,507,288.68, down 6.55% from CNY 54,048,074.83 year-on-year[3] - The basic earnings per share for the period was CNY 0.2007, a decrease of 5.06% compared to CNY 0.2114 in the same period last year[3] - The diluted earnings per share also stood at CNY 0.2007, reflecting a 5.06% decline from the previous year[3] - Net profit for Q1 2025 was ¥59,010,897.88, a decrease of 6.4% from ¥63,026,922.86 in Q1 2024[17] - Earnings per share for Q1 2025 were ¥0.2007, down from ¥0.2114 in Q1 2024[18] Assets and Liabilities - The company's total assets increased by 27.45% to CNY 7,140,206,593.52 from CNY 5,602,253,258.06 at the end of the previous year[4] - The company's current assets totaled ¥6,887,944,967.70, up from ¥5,353,355,557.46, indicating an increase of about 28.7%[11] - Accounts receivable rose significantly to ¥2,278,910,193.16 from ¥1,472,052,100.51, reflecting an increase of approximately 54.7%[10] - Inventory increased to ¥2,662,122,969.12, compared to ¥1,573,274,085.46, marking a growth of around 69.5%[11] - The total liabilities of the company reached ¥5,398,834,431.35, up from ¥3,919,565,784.09, which is an increase of about 37.7%[13] - The company's short-term borrowings increased to ¥718,520,747.02 from ¥628,482,348.09, showing a rise of approximately 14.3%[12] - Total cash inflow from investment activities was $1.74 billion, up from $1.01 billion, representing a significant increase of about 72%[22] - Net cash flow from investment activities was $501.37 million, compared to $199.57 million, indicating a growth of approximately 151%[22] Cash Flow - The net cash flow from operating activities was negative at CNY -645,780,630.42, an improvement from CNY -698,997,933.99 in the same period last year[3] - Cash inflow from operating activities in Q1 2025 was ¥2,060,997,031.26, slightly down from ¥2,076,742,543.57 in Q1 2024[21] - Cash paid for purchasing goods and services in Q1 2025 was ¥2,555,332,471.71, compared to ¥2,643,621,303.85 in Q1 2024[21] - Cash inflow from financing activities totaled $325 million, down from $602 million, reflecting a decrease of about 46%[22] - Net cash flow from financing activities was $81.55 million, a decline from $290.49 million, representing a decrease of approximately 72%[22] - The net increase in cash and cash equivalents was -$64.78 million, compared to -$211.17 million, showing an improvement of about 69%[23] - The ending balance of cash and cash equivalents was $321.85 million, down from $338.99 million, indicating a decrease of approximately 5%[23] Shareholder Equity - The equity attributable to shareholders of the listed company rose by 3.53% to CNY 1,574,153,747.87 from CNY 1,520,445,416.61 at the end of the previous year[4] - The total equity remained stable at ¥268,800,134.00, unchanged from the previous period[13] - The total equity attributable to shareholders increased to ¥1,574,153,747.87 from ¥1,520,445,416.61[14] Research and Development - Research and development expenses for Q1 2025 totaled ¥14,163,425.20, an increase from ¥13,560,719.92 in Q1 2024[16] Other Information - The company has not disclosed any new product developments or market expansion strategies during the reporting period[9] - There were no changes in the top 10 shareholders or their shareholding status due to securities lending activities[9] - The company reported non-recurring gains of CNY 3,429,365.98 after accounting for tax and minority interests[6] - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[23]

前十大流通股东累计持有： 17863.92万股，累计占流通股比： 66.47%，较上期变化：0.00 。 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 中国农业生产资料集团有限公司 | 13507.20 | 50.25 | 不变 | | 广东益隆投资有限公司 | 2540.16 | 9.45 | 不变 | | 北京中农利成管理咨询有限公司 | 322.56 | 1.20 | 不变 | | 中国农业银行股份有限公司-大成新锐产业混合型证券投 资基金 | 292.63 | 1.09 | 新进 | | 浙江浙农金泰生物科技有限公司 | 273.60 | 1.02 | 不变 | | 刘锋 | 205.60 | 0.76 | 不变 | | 中国对外经济贸易信托有限公司-外贸信托-仁桥泽源股票 | | | | | 私募证券投资基金 | 203.51 | 0.76 | 不变 | | 何海林 | 195.51 | 0.73 | 不变 | | 广发证券股份有限公司-大成睿景灵活配置混合型证券投 | | | | | ...

证券代码：603970 证券简称：中农立华 公告编号：2025-019 中农立华生物科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025年5月16日 14点30分 召开地点：北京市西城区宣武门外大街甲1号环球财讯中心会议室 (五)网络投票的系统、起止日期和投票时间 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025年5月16日 至2025年5月16日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的交易时间 段，即9:15-9:25，9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回 ...

证券代码：603970 证券简称：中农立华 公告编号：2025-019 中农立华生物科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 16 日 14 点 30 分 召开地点：北京市西城区宣武门外大街甲 1 号环球财讯中心会议室 (五) 网络投票的系统、起止日期和投票时间 股东大会召开日期：2025年5月16日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 16 日 至2025 年 5 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日 ...